Submit Manuscript Now
Current issue Archive Authors Profile
Research Articles Supplement 2 · 2019 · pp. 146–157 · Issue page

UPDATING THE SIGNIFICANCE OF SCREENING AND TRIAGE METHODS OF CERVICAL LESIONS – REVIEW

RU
Ruxandra STĂNCULESCU1
VA
Vasilica BAUȘIC2
LI
Linda CLUCERU POPA3
CI
Ciprian COROLEUCĂ4
RA
Ramona DRAGOMIR5
CĂ
Cătălin COROLEUCĂ6
AL
Alexandra BAUȘIC7
BO
Bogdan SOCEA8
MA
Manuela RUSSU9
EL
Elvira BRĂTILĂ10
1 Associate Professor, MD, PhD in Medicine, Department of Obstetrics and Gynaecology, University of Medicine and
2 Pharmacy “Carol Davila”, Bucharest, Romania, “Sf. Pantelimon” Clinical Emergency Hospital, Bucharest, Romania,
3 University Lecturer, MD, PhD in Medicine, Molecular Biology Department, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
4 University Assistant, MD, PhD Student in Medicine, Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, “Panait Sîrbu” Clinical Hospital, Bucharest, Romania
5 Resident Physician, MD, PhD Student in Medicine, Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, “Polizu” Clinical Hospital, Bucharest, Romania
6 Specialist Physician, MD, PhD Student in Medicine, Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, “Panait Sîrbu” Clinical Hospital, Bucharest, Romania
7 Resident Physician, MD, Department of Obstetrics and Gynaecology, “Panait Sîrbu” Clinical Hospital, Bucharest, Romania
8 University Lecturer, MD, PhD in Medicine, Department of Surgery, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, “Sf. Pantelimon” Clinical Emergency Hospital, Bucharest, Romania
9 University Professor, MD, PhD in Medicine, Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, “Dr. Ioan Cantacuzino” Clinical Hospital, Bucharest, Romania
10 University Professor, MD, PhD in Medicine, Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, “Panait Sîrbu” Clinical Hospital, Bucharest, Romania
Corresponding author: [email protected]
Accepted 29 March 2026
Available Online 20 July 2019
Abstract
THE IDENTIFICATION OF WOMEN HAVING OR BEING ABLE TO DEVELOP CERVICAL CANCER IS A MAJOR CONCERN WORLDWIDE EXPRESSED BY ENDEAVORS TO IMPLEMENT NEW METHODS OF SCREENING AND TRIAGE FOR PRECANCEROUS CERVICAL LESIONS (PCL). THE PRESENT WORK ENCOMPASSES RESULTS OF MANY TRIALS AND OBSERVATIONAL STUDIES PUBLISHED ON INTERNATIONAL DATABASES DURING LAST 10 YEARS. THE PURPOSE OF CURRENT STUDY IS TO HIGHLIGHT THE FEATURES OF ADVANCED BIOTECHNOLOGIES, CONCERNING THEIR CAPACITY OF LEADING TO AN EARLY RIGHT DIAGNOSIS SUPPO RTING, TO COMPARE THE EFICACITY OF THESE TESTS SUCH SENSITIVITY AS SPECIFICITY, TO TRIAGE BETWEEN REGRESSIVE AND PROGRESSIVE PCL, TO HIGHLIGHT THE DIFFERENCE CONCERNING SCREENING METHODS ADOPTED BY THE NATIONAL PROGRAMMES WORLDWIDE. THE RESULTS SHOWED THAT PAP TEST IS AN EXPENSIVE METHOD, WITH HIGH LEVEL OF SUBJECTIVE ASSESSMENT AND WITHOUT POSSIBILITY OF DISCRIMINATION BETWEEN DIFERENT KINDS OF CYTOLOGIES. HUMAN PAPILLOMAVIRUS (HPV) GENOTYPE ALONE DOESN’T ALLOW TO DISTINGUISH TRANSIENT VERSUS PROGRESSIVE H PV INFECTION. IMMUNOSTAINING CYCLINE P16INK4A AND THE MORE PERFORMANT TEST, D UAL TEST P16INK4A/ KI 67 ALLOW THE TRIAGE OF CASES ABLE TO DEVELOP CANCER USED ALONE OR AS CO -TEST TO PRIMARY HPV SCREENING. PRIMARY CERVICAL SCREENING WITH HPV GENOTYPE ASSOCIATE WITH ONE OF CO -CIYTOLOGIC TEST IMPROVE THE ACCURACY OF AN EARLY DIAGNOSIS.
Keywords
CERVICAL CANCER PRECANCEROUS CERVICAL LESIONS BIOTECHNOLOGIES PAP
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Abreu, André L P, Raquel P Souza, Fabrícia Gimenes, and Marcia E L Consolaro. 2012. "A Review Of Methods For Detect Human Papillomavirus Infection". Virology Journal 9 (1): 262. doi:10.1186/1743-422x- 9-262
[2]
Arbyn, M., F. Buntinx, M. V. Ranst, E. Paraskevaidis, P. Martin-Hirsch, and J. Dillner. 2004. "Virologic Versus Cytologic Triage Of Women With Equivocal Pap Smears: A Meta-Analysis Of The Accuracy To Detect High-Grade Intraepithelial Neoplasia". JNCI Journal Of The National Cancer Institute 96 (4): 280-293. doi:10.1093/jnci/djh037
[3]
Arbyn, M., P.J.F. Snijders, C.J.L.M. Meijer, J. Berkhof, K. Cuschieri, B.J. Kocjan, and M. Poljak . 2015. " Which High -Risk HPV Assays Fulfil Criteria For Use In Primary Cervical Cancer Screening?". Clinical Microbiology And Infection 21 (9): 817-826. doi:10.1016/j.cmi.2015.04.015
[4]
Arbyn, Marc, Christine Bergeron, Paul Klinkhamer, Pierre Martin-Hirsch, Albertus G. Siebers, and Johan Bulten . 2008. " Liquid Co mpared With Conventional Cervical Cytolog y". Obstetrics & Gynecology 111 (1): 167-177. doi:10.1097/01.aog.0000296488.85807.b3
[5]
Castle, Philip E, Mark H Stoler, Thomas C Wright, Abha Sharma, Teresa L Wright, and Catherine M Behrens. 2011. " Performance Of Car cinogenic Human Papillomavirus (HPV) Testing And HPV16 Or HPV18 Genotyping For Cervical Cancer Screening Of Women Aged 25 Years And Older: A Subanalysis Of The ATHENA Study". The Lancet Oncology 12 (9): 880-890. doi:10.1016/s1470-2045(11)70188-7
[6]
Cong, X., Cox, D. and Cantor, S . (2007). „ Bayesian meta -analysis of Papanicolaou smear accuracy“, Gynecologic Oncology, 107(1), pp.S133-S137
[7]
Cuschieri, Kate, Guglielmo Ronco, Attila Lorincz, Laurie Smith, Gina Ogilvie, Lisa Mirabello, and Francesca Carozzi et al. 2018. "Eurogin Roadmap 2017: Triage Strategies For The Management Of HPV- Positive Women In Cervical Screening Programs ". International Journal Of Cancer 143 (4): 735 -745. doi:10.1002/ijc.31261
[8]
Heideman, D. A. M., A. T. Hesselink, J. Berkhof, F. van Kemenade, W. J. G. Me lchers, N. Fransen Daalmeijer, M. Verkuijten, C. J. L. M. Meijer, and P. J. F. Snijders. 2011. "Clinical Validation Of The Cobas 4800 HPV Test For Cervical Screening Purposes". Journal Of Clinical Microbiology 49 (11): 3983- 3985. doi:10.1128/jcm.05552-11
[9]
Ho, Chih-Ming, Bor-Heng Lee, Shwu-Fen Chang, Tsai-Yen Chien, Shih-Hung Huang, Chiu-Cho Yan, and Weng-Fang Cheng. 2011. "Integration Of Human Papillomavirus Correlates With High Levels Of Viral Oncogene Transcripts In Cervical Carcinogenesis ". Virus Research 161 (2): 124 -130. doi:10.1016/j.virusres.2011.06.012
[10]
Johnson, Lawrence R., Cindi R. Starkey, James Palmer, James Taylor, Spencer Stout, Stephanie Holt, and Ryan Hendren et al. 2008. "A Comparison Of Two Methods To Determine The Presence Of High-Risk HPV C ervical Infections ". American Journal Of Clinical Pathology 130 (3): 401 -408. doi:10.1309/4dxeafg2jxyf34n3
[11]
MacDonald, CF. 2019. "Assessing Secondary Prevention Methods For Cervical Cancer: Costs And Benefits In Managed Care ". AJMC. https://www.ajmc.com/journals/supplement/2008/2008-06-vol14- n6suppl/jun08-3383ps185-s192
[12]
Martínez, Samuel Bernal, José Carlos Palomares, Antonio Artura, Manuel Parra, Jose Luis Cabezas, Jose Ma Romo, and Estrella Martín -Mazuelos. 2012. " Comparison Of The Cobas 4800 Human Papillomavirus Test Against A Combination Of The Amplicor Human Papillomavirus And The Linear Array Tests For Detection Of HPV Types 16 And 18 In Cervical Samples". Journal Of Virological Methods 180 (1- 2): 7-10. doi:10.1016/j.jviromet.2011.12.002
[13]
Rebolj, Matejka, Janet Rimmer, Karin Denton, John Tidy, Christopher Mathews, Kay Ellis, and John Smith et al. 2019. " Primary Cervical Screeni ng With Hi gh Risk Human Papillomavirus Testing: Observational Study". BMJ, l240. doi:10.1136/bmj.l240
[14]
Reuschenbach, Miriam, Andreas Clad, Christina von Knebel Doeberitz, Nicolas Wentzensen, Janina Rahmsdorf, Frauke Schaffrath, Henrik Griesser, Nikolaus Freudenberg, and Magnus von Knebel Doeberitz. 2010. "Performance Of P16ink4a-Cytology, HPV Mrna, And HPV DNA Testing To Identify High Grade Cervical Dysplasia In Women With Abnormal Screening Results". Gynecologic Oncology 119 (1): 98-
[105]
doi:10.1016/j.ygyno.2010.06.011
[15]
Siebers, Albertus G., Paul J. J. M. Klinkhamer, Johanna M. M. Grefte, Leon F. A. G. Massuger, Judith E. M. Vedder, Angelique Beijers-Broos, Johan Bulten, and Marc Arbyn. 2009. "Comparison Of Liquid- Based Cytology With Conventional Cytology For Detection Of Cervical Cancer Precursors ". JAMA 302 (16): 1757. doi:10.1001/jama.2009.1569
[16]
Stănculescu, R., Brătilă E., Baușic V and Vlădescu T. 2013. “ The triage of low -grade cytological abnormalities by the immunocytological expression of cyclin -dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+”. Rom J Morphol Embryol. 54(4):1061-1065
[17]
Stanculescu, Ruxandra. 2016. "Biotechnologies Involved In Differentiation Of Cervical Lesions". Human Papillomavirus - Research In A Global Perspective. doi:10.5772/62729
[18]
Tsoumpou, I., M. Arbyn, M. Kyrgiou, N. Wentzensen, G. Koliopoulos, P. Martin-Hirsch, V. Malamou- Mitsi, and E. Paraskevaidis. 2009. "P16ink4a Immunostaining In Cytological And Histological Specimens From The Uterine Cervix: A Systematic Review And Meta-Analysis". Cancer Treatment Reviews 35 (3): 210-
[220]
doi:10.1016/j.ctrv.2008.10.005
[19]
Wentzensen, Nicolas, Barbara Fetterman, Diane Tokugawa, Mark Schiffman, Philip E. Cast le, Shannon N. Wood, Eric Stiemerling, Nancy Poitras, Thomas Lorey, and Walter Kinney . 2014. "Interobserver Reproducibility And A ccuracy Of P16/Ki -67 Dual -Stain Cytology In Cervical Cancer Screening". Cancer Cytopathology 122 (12): 914-920. doi:10.1002/cncy.21473
[20]
Wentzensen, Nicolas, Barbara Fetterman, Philip E. Castle, Mark Schiffman, Shannon N. Wood, Eric Stiemerling, and Diane Tokugawa et al. 2015. "P16/Ki-67 Dual Stain Cytology For Detection Of Cervical Precancer In HPV -Positive Women ". Journal Of The N ational Cancer Institute 107 (12): djv257. doi:10.1093/jnci/djv257
[21]
Wentzensen, Nicolas, Christine Bergeron, Frederic Cas, Denise Eschenbach, Svetlana Vinokurova, and Magnus von Knebel Doeberitz . 2005. " Evaluation Of A Nuclear Score For P16ink4a -Stained Cervical Squamous Cells In Liquid-Based Cytology Samples". Cancer 105 (6): 461-467. doi:10.1002/cncr.21378
[22]
Wentzensen, Nicolas, Megan A. Clarke, Renee Bremer, Nancy Poitras, Diane Tokugawa, Patricia E. Goldhoff, and Philip E. Castle et al. 2019. "Clinical Evaluation Of Human Papillomavirus Screening With P16/Ki-67 Dual Stain Triage In A Large Organized Cervical Cancer Screening Program ". JAMA Internal Medicine. doi:10.1001/jamainternmed.2019.0306
[23]
Johnson, Lawrence R., Cindi R. Starkey, James Palmer, James Taylor, Spencer Stout, Stephanie Holt, and Ryan Hendren et al. 2008. "A Comparison Of Two Methods To Determine The Presence Of High-Risk HPV Cervical Infections". American Journal Of Clinical Pathology 130 (3): 401 -408. doi:10.1309/4dxeafg2jxyf34n3
[24]
Abreu, André L P, Raquel P Souza, Fabrícia Gimenes, and Marcia E L Consolaro. 2012. "A Review Of Methods For Detect Human Papillomavirus Infection". Virology Journal 9 (1): 262. doi:10.1186/1743-422x- 9-262
[25]
Ho, Chih-Ming, Bor-Heng Lee, Shwu-Fen Chang, Tsai-Yen Chien, Shih-Hung Huang, Chiu-Cho Yan, and Weng-Fang Cheng. 2011. "Integration Of Human Papillomavirus Correlates With High Levels Of Viral Oncogene Transcripts In Cervical Carcinogenesis". Virus Research 161 (2): 124 -130. doi:10.1016/j.virusres.2011.06.012.
[26]
Arbyn, M., P.J.F. Snijders, C.J.L.M. Meijer, J. Berkhof, K. Cuschieri, B.J. Kocjan, and M. Poljak. 2015. "Which High -Risk HPV Assays Fulfil Criteria For Use In Primary Cervical Cancer Screening?". Clinical Microbiology And Infection 21 (9): 817-826. doi:10.1016/j.cmi.2015.04.015
[27]
Reuschenbach, Miriam, Andreas Clad, Christina von Knebel Doeberitz, Nicolas Wentzensen, Janina Rahmsdorf, Frauke Schaffrath, Henrik Griesser, Nikolaus Freudenberg, and Magnus von Knebel Doeberitz. 2010. "Performance Of P16ink4a -Cytology, HPV Mrna, And HPV DNA Testing To Identify High Grade Cervical Dysplasia In Women With Abnormal Screening Results". Gynecologic Oncology 119 (1): 98-105. doi:10.1016/j.ygyno.2010.06.011
[28]
Tsoumpou, I., M. Arbyn, M. Kyrgiou, N. Wentzensen, G. Koliopoulos, P. Martin-Hirsch, V. Malamou- Mitsi, and E. Paraskevaidis. 2009. "P16ink4a Immunostaining In Cytological And Histological Specimens From The Uterine Cervix: A Systematic Review And Meta -Analysis". Cancer Treatment Reviews 35 (3): 210-220. doi:10.1016/j.ctrv.2008.10.005
[29]
Stănculescu, Ruxandra, Elvira Brătilă, Vasilica Baușic and Teodora Vlădescu. 2013. “The triage of low- grade cytological abnormalities by the immunocytological expression of cyclin -dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+”. Rom J Morphol Embryol. 54(4):1061-1065
[30]
Carozzi F, Gillio -Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi -Rossi P, Segnan N, Cuzick J, Ronco G; 2013, NTCC working group. Risk of high -grade cervical intraepithelial neoplasia during follow -up in HPV -positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial, Lancet Oncol. 2013;14: 168–176
[31]
Wentzensen, Nicolas, Christine Bergeron, Frederic Cas, Denise Eschenbach, Svetlana Vinokurova, and Magnus von Knebel Doeberitz. 2005. "Evaluation Of A Nuclear Score For P16ink4a-Stained Cervical Squamous Cells In Liquid-Based Cytology Samples". Cancer 105 (6): 461-467. doi:10.1002/cncr.21378.
[32]
Cuschieri, Kate, Guglielmo Ronco, Attila Lorincz, Laurie Smith, Gina Ogilvie, Lisa Mirabe llo, and Francesca Carozzi et al. 2018. "Eurogin Roadmap 2017: Triage Strategies For The Management Of HPV- Positive Women In Cervical Screening Programs". International Journal Of Cancer 143 (4): 735 -745. doi:10.1002/ijc.31261.
[33]
Wentzensen, Nicolas, Barbara Fetterman, Diane Tokugawa, Mark Schiffman, Philip E. Castle, Shannon N. Woo d, Eric Stiemerling, Nancy Poitras, Thomas Lorey, and Walter Kinney. 2014. "Interobserver Reproducibility And Accuracy Of P16/Ki -67 Dual -Stain Cytology In Cervical Cancer Screening". Cancer Cytopathology 122 (12): 914-920. doi:10.1002/cncy.21473.
[34]
Wentzensen, Nicolas, Barbara Fetterman, Philip E. Castle, Mark Schiffman, Shannon N. Wood, Eric Stiemerling, and Diane Tokugawa et al. 2015. "P16/Ki-67 Dual Stain Cytology For Detection Of Cervical Precancer In HPV -Positive Women". Journal Of The National Cancer In stitute107 (12): djv257. doi:10.1093/jnci/djv257.